Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KHAPZORY vs KEPPRA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lefamulin, a pleuromutilin antibiotic, inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, specifically to the peptidyl transferase center (PTC) at the A-site cleft, thereby blocking peptide bond formation and protein translation.
Levetiracetam binds to synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. It also inhibits high-voltage N-type calcium channels and reduces GABAergic and glycinergic inhibition.
Community-acquired bacterial pneumonia (CABP) in adults,Off-label: None established
Adjunctive therapy for partial-onset seizures (FDA),Adjunctive therapy for myoclonic seizures in juvenile myoclonic epilepsy (FDA),Adjunctive therapy for primary generalized tonic-clonic seizures (FDA),Off-label: Bipolar disorder, migraine prophylaxis, neuropathic pain, status epilepticus
KHAPZORY (lenalidomide) 25 mg orally once daily on days 1-21 of repeated 28-day cycles.
500 mg orally twice daily, titrated up to 1500 mg twice daily as tolerated.
Terminal elimination half-life: 15-20 hours; clinical context: supports once-daily dosing
6-8 hours in adults; prolonged to 10-18 hours in renal impairment (Cr Cl <30 m L/min); clinical context: dosing interval adjustment required in renal disease.
Primarily metabolized by cytochrome P450 3A4 (CYP3A4) and to a lesser extent by CYP2D6 and CYP2C8; also undergoes conjugation and oxidation.
Levetiracetam is not extensively metabolized; ~66% of the dose is excreted unchanged in urine. Metabolism occurs via enzymatic hydrolysis of the acetamide group, independent of cytochrome P450. Major metabolite is the carboxylic acid derivative (ucb L057), which is pharmacologically inactive.
Renal: 90% as unchanged drug; fecal: <5% as metabolites
Renal: 66% unchanged; 27% as inactive metabolite; 0.3% fecal.
90-95% bound to albumin
<10% bound to plasma proteins (albumin).
0.3-0.4 L/kg; clinical meaning: distributes primarily into extracellular fluid
0.5-0.7 L/kg; approximates total body water; clinical meaning: extensive distribution into tissues, including brain.
Oral: 70-85%
Oral: 100% (immediate-release formulation); IV: 100%.
Cr Cl ≥60 m L/min: 25 mg daily. Cr Cl 30-60 m L/min: 10 mg daily. Cr Cl <30 m L/min (not requiring dialysis): 15 mg every 48 hours. Cr Cl <30 m L/min (requiring dialysis): 5 mg once daily; on dialysis days, administer after dialysis.
Cr Cl 50-80 m L/min: 500-1000 mg every 12 hours; Cr Cl 30-49 m L/min: 250-750 mg every 12 hours; Cr Cl <30 m L/min: 250-500 mg every 12 hours; ESRD on dialysis: 500-1000 mg once daily with 250-500 mg supplemental dose after dialysis.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Initiate at 10 mg daily. Child-Pugh Class C: Initiate at 5 mg daily; may titrate based on tolerance.
No specific adjustment for hepatic impairment; use caution in severe hepatic impairment.
Safety and efficacy not established for patients <18 years; no recommended dosing.
1 month to <6 months: 7 mg/kg twice daily, titrate to 21 mg/kg twice daily; 6 months to <4 years: 10 mg/kg twice daily, titrate to 25 mg/kg twice daily; 4 to <16 years: 10 mg/kg twice daily, titrate to 30 mg/kg twice daily (maximum 3000 mg/day).
No specific dose adjustment based on age alone; adjust for renal function as per renal adjustment guidelines; monitor for myelosuppression, thromboembolic events, and peripheral neuropathy more frequently.
Start at 250-500 mg twice daily; titrate slowly due to age-related renal function decline.
None
None
QTc interval prolongation (avoid in patients with known QTc prolongation, electrolyte disturbances, or concurrent use of QTc-prolonging agents),Hepatotoxicity (monitor liver function tests; discontinue if signs of liver injury occur),Clostridioides difficile-associated diarrhea (CDAD),Hypersensitivity reactions including anaphylaxis,Avoid use in patients with moderate to severe hepatic impairment (Child-Pugh B or C)
Behavioral and psychiatric symptoms: psychosis, aggression, suicidal ideation,Somnolence and fatigue, dose-dependent,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hematologic abnormalities: decreased red blood cell, white blood cell, and platelet counts,Acute kidney injury (rare), intercurrent illness may increase risk,Avoid abrupt discontinuation to minimize seizure exacerbation or status epilepticus
Hypersensitivity to lefamulin or any component of the formulation,Concurrent use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) reduces lefamulin exposure; avoid coadministration
Hypersensitivity to levetiracetam or any of its components
No significant food interactions known. Avoid alcohol as it may increase risk of methotrexate toxicity.
No significant food interactions. Levetiracetam absorption is not affected by food. Avoid alcohol as it may increase CNS depression.
KHAPZORY (levonorgestrel) is a progestin-only emergency contraceptive. Limited human data; no increased risk of major birth defects in case of inadvertent use during pregnancy. Theoretically, no known teratogenic effect in any trimester.
Increased risk of major congenital malformations, particularly neural tube defects (e.g., spina bifida), cleft palate, and cardiovascular defects, especially with first trimester exposure. Risk is dose-dependent and higher with polytherapy. Second and third trimester exposure may be associated with neurodevelopmental impairments.
Levonorgestrel is excreted into human milk; estimated infant dose < 1% of maternal dose. M/P ratio not reported. Generally considered compatible with breastfeeding.
Levetiracetam is excreted into breast milk with an M/P ratio of approximately 1.0. Infant serum levels are about 10-30% of maternal levels. Generally considered compatible with breastfeeding, but monitor infant for drowsiness, poor feeding, and developmental milestones.
Not indicated for use during pregnancy. No dose adjustment applicable.
Pregnancy increases levetiracetam clearance by 30-60%, especially in the second and third trimesters. Monitor serum trough concentrations every 1-2 months and increase dose as needed to maintain therapeutic levels. Postpartum, reduce dose to pre-pregnancy levels within the first week.
KHAPZORY (levoleucovorin) is used as a rescue agent after high-dose methotrexate therapy to prevent severe toxicity. Monitor serum methotrexate levels closely; administer leucovorin until methotrexate level is <5×10^-8 M. Adjust dose in renal impairment. Not interchangeable with folic acid.
Levetiracetam (Keppra) is a broad-spectrum AED with minimal drug interactions. Dosing must be adjusted for renal function (Cr Cl <80 m L/min). Monitor for behavioral changes, especially in pediatric patients. IV formulation can be administered without ECG monitoring. No need for therapeutic drug monitoring; efficacy and tolerability guide dosing.
Take this medication exactly as prescribed, usually every 6 hours for a set number of doses.,Do not skip doses, as this may increase the risk of methotrexate toxicity.,Inform your doctor if you experience shortness of breath, rash, or signs of allergic reaction.,Keep all appointments for blood tests to monitor methotrexate levels.,Avoid taking folic acid supplements unless directed by your doctor.
Take exactly as prescribed; do not stop suddenly as withdrawal seizures may occur.,Report any unusual mood changes, depression, or aggressive behavior to your doctor.,May cause dizziness or drowsiness; avoid driving until effects are known.,Take with or without food; do not crush extended-release tablets.,Drink plenty of fluids to prevent kidney stones, though not a common side effect.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KHAPZORY vs KEPPRA, answered by our medical review team.
KHAPZORY is a Antiepileptic that works by Lefamulin, a pleuromutilin antibiotic, inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, specifically to the peptidyl transferase center (PTC) at the A-site cleft, thereby blocking peptide bond formation and protein translation.. KEPPRA is a Antiepileptic that works by Levetiracetam binds to synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. It also inhibits high-voltage N-type calcium channels and reduces GABAergic and glycinergic inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KHAPZORY and KEPPRA depend on the specific clinical indication. These are both Antiepileptic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KHAPZORY is: KHAPZORY (lenalidomide) 25 mg orally once daily on days 1-21 of repeated 28-day cycles.. The standard adult dose of KEPPRA is: 500 mg orally twice daily, titrated up to 1500 mg twice daily as tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KHAPZORY and KEPPRA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KHAPZORY is classified as Category C. KHAPZORY (levonorgestrel) is a progestin-only emergency contraceptive. Limited human data; no increased risk of major birth defects in case of inadvertent use during pregnancy. The. KEPPRA is classified as Category C. Increased risk of major congenital malformations, particularly neural tube defects (e.g., spina bifida), cleft palate, and cardiovascular defects, especially with first trimester e. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.